CN106540268A - 一种TDNs‑AS1411‑核酸药物复合纳米材料载药系统及其制备方法 - Google Patents
一种TDNs‑AS1411‑核酸药物复合纳米材料载药系统及其制备方法 Download PDFInfo
- Publication number
- CN106540268A CN106540268A CN201610940890.3A CN201610940890A CN106540268A CN 106540268 A CN106540268 A CN 106540268A CN 201610940890 A CN201610940890 A CN 201610940890A CN 106540268 A CN106540268 A CN 106540268A
- Authority
- CN
- China
- Prior art keywords
- nucleic acid
- drug
- tdns
- dna
- composite nano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 49
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 44
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 44
- 239000002086 nanomaterial Substances 0.000 title claims abstract description 28
- 239000002131 composite material Substances 0.000 title claims abstract description 27
- 229940079593 drug Drugs 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- -1 AS1411 nucleic acid Chemical class 0.000 title abstract 3
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 18
- 238000002156 mixing Methods 0.000 claims abstract description 10
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 claims description 13
- 241000764238 Isis Species 0.000 claims description 13
- 238000005417 image-selected in vivo spectroscopy Methods 0.000 claims description 13
- 238000012739 integrated shape imaging system Methods 0.000 claims description 13
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 10
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 5
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 5
- 108091034117 Oligonucleotide Proteins 0.000 claims description 4
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 4
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 4
- 108700011259 MicroRNAs Proteins 0.000 claims description 3
- 108020004459 Small interfering RNA Proteins 0.000 claims description 2
- ZWXNIBJNMPZZKZ-JILWZBBZSA-A afovirsen sodium Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([S-])(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)O)C1 ZWXNIBJNMPZZKZ-JILWZBBZSA-A 0.000 claims description 2
- JMLGXYWHNOKLBE-HOTXNYTESA-A alicaforsen sodium Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)CO)[C@@H](OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)C1 JMLGXYWHNOKLBE-HOTXNYTESA-A 0.000 claims description 2
- NMYKBZSMOUFOJV-FJSWQEPZSA-N aprinocarsen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)CO)[C@@H](OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)C1 NMYKBZSMOUFOJV-FJSWQEPZSA-N 0.000 claims description 2
- DQRZDIMTJNNJHB-UHFFFAOYSA-N isis 2922 Chemical compound O=C1NC(=O)C(C)=CN1C1OC(COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(O)=S)C(OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(S)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)O)C1 DQRZDIMTJNNJHB-UHFFFAOYSA-N 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 239000002679 microRNA Substances 0.000 claims description 2
- 239000002924 silencing RNA Substances 0.000 claims description 2
- OMEUGRCNAZNQLN-UHFFFAOYSA-N isis 5132 Chemical compound O=C1NC(=O)C(C)=CN1C1OC(COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(S)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)CO)C(O)C1 OMEUGRCNAZNQLN-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 210000003712 lysosome Anatomy 0.000 abstract description 3
- 230000001868 lysosomic effect Effects 0.000 abstract description 3
- 230000008685 targeting Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 4
- 108091023037 Aptamer Proteins 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000007233 immunological mechanism Effects 0.000 description 2
- 230000006674 lysosomal degradation Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108091007773 MIR100 Proteins 0.000 description 1
- 108091007780 MiR-122 Proteins 0.000 description 1
- 108091034054 MiR-138 Proteins 0.000 description 1
- 108091007419 MiR-27 Proteins 0.000 description 1
- 108091027966 Mir-137 Proteins 0.000 description 1
- 108091061943 Mir-218 microRNA precursor family Proteins 0.000 description 1
- 108091062170 Mir-22 Proteins 0.000 description 1
- 108091060585 Mir-31 Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 108010037721 cytase Proteins 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000031852 maintenance of location in cell Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108091064157 miR-106a stem-loop Proteins 0.000 description 1
- 108091051828 miR-122 stem-loop Proteins 0.000 description 1
- 108091056924 miR-124 stem-loop Proteins 0.000 description 1
- 108091044988 miR-125a stem-loop Proteins 0.000 description 1
- 108091051410 miR-130 stem-loop Proteins 0.000 description 1
- 108091050366 miR-130-1 stem-loop Proteins 0.000 description 1
- 108091054878 miR-130-2 stem-loop Proteins 0.000 description 1
- 108091079016 miR-133b Proteins 0.000 description 1
- 108091043162 miR-133b stem-loop Proteins 0.000 description 1
- 108091043249 miR-135-1 stem-loop Proteins 0.000 description 1
- 108091064876 miR-135-2 stem-loop Proteins 0.000 description 1
- 108091030496 miR-138 stem-loop Proteins 0.000 description 1
- 108091060382 miR-140 stem-loop Proteins 0.000 description 1
- 108091043612 miR-146b stem-loop Proteins 0.000 description 1
- 108091026495 miR-148b stem-loop Proteins 0.000 description 1
- 108091091751 miR-17 stem-loop Proteins 0.000 description 1
- 108091044046 miR-17-1 stem-loop Proteins 0.000 description 1
- 108091065423 miR-17-3 stem-loop Proteins 0.000 description 1
- 108091083606 miR-1908 stem-loop Proteins 0.000 description 1
- 108091039097 miR-193b stem-loop Proteins 0.000 description 1
- 108091054642 miR-194 stem-loop Proteins 0.000 description 1
- 108091054189 miR-196a stem-loop Proteins 0.000 description 1
- 108091064378 miR-196b stem-loop Proteins 0.000 description 1
- 108091031479 miR-204 stem-loop Proteins 0.000 description 1
- 108091062762 miR-21 stem-loop Proteins 0.000 description 1
- 108091041631 miR-21-1 stem-loop Proteins 0.000 description 1
- 108091044442 miR-21-2 stem-loop Proteins 0.000 description 1
- 108091048308 miR-210 stem-loop Proteins 0.000 description 1
- 108091040176 miR-218 stem-loop Proteins 0.000 description 1
- 108091061970 miR-26a stem-loop Proteins 0.000 description 1
- 108091070404 miR-27b stem-loop Proteins 0.000 description 1
- 108091030789 miR-302 stem-loop Proteins 0.000 description 1
- 108091053185 miR-302d stem-loop Proteins 0.000 description 1
- 108091055059 miR-30c stem-loop Proteins 0.000 description 1
- 108091042879 miR-326 stem-loop Proteins 0.000 description 1
- 108091029119 miR-34a stem-loop Proteins 0.000 description 1
- 108091039521 miR-363 stem-loop Proteins 0.000 description 1
- 108091056495 miR-363-1 stem-loop Proteins 0.000 description 1
- 108091025820 miR-363-2 stem-loop Proteins 0.000 description 1
- 108091080309 miR-483 stem-loop Proteins 0.000 description 1
- 108091039994 miR-486 stem-loop Proteins 0.000 description 1
- 108091028769 miR-540 stem-loop Proteins 0.000 description 1
- 108091034121 miR-92a stem-loop Proteins 0.000 description 1
- 108091041519 miR-92a-3 stem-loop Proteins 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- OGIAAULPRXAQEV-UHFFFAOYSA-N odn 2216 Chemical compound O=C1NC(=O)C(C)=CN1C1OC(COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(O)=O)C(OP(O)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)O)C1 OGIAAULPRXAQEV-UHFFFAOYSA-N 0.000 description 1
- UIRLPEMNFBJPIT-UHFFFAOYSA-N odn 2395 Chemical compound O=C1NC(=O)C(C)=CN1C1OC(COP(O)(O)=O)C(OP(O)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)O)C1 UIRLPEMNFBJPIT-UHFFFAOYSA-N 0.000 description 1
- KDWFDOFTPHDNJL-TUBOTVQJSA-N odn-2006 Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=S)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=S)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(S)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)[C@@H](O)C1 KDWFDOFTPHDNJL-TUBOTVQJSA-N 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/52—Physical structure branched
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明公开了一种TDNs‑AS1411‑核酸药物复合纳米材料载药系统的制备方法,包括以下步骤:将AS1411和核酸药物分别与DNA四面体结合,选出分别带有AS1411和核酸药物的四条DNA单链,混合,然后加入TM buffer中,混匀后置于PCR仪内,将温度迅速升到95℃稳定10min,再冷却至4℃稳定20min,得TDNs‑AS1411‑核酸药物复合纳米材料载药系统。该载药系统所可直接对细胞核发挥作用,药物不会被溶酶体降低,靶向性强,可有效发挥药物作用,针对性强。
Description
技术领域
本发明属于生物医药技术领域,具体涉及一种TDNs-AS1411-核酸药物复合纳米材料载药系统及其制备方法。
背景技术
DNA四面体纳米结构(TDNs)是基于DNA纳米技术自组装合成的具有合成方法简单、产率高、结构稳定、机械性能优越、分子修饰位点丰富等优点,在分子诊断、生物成像、分子输送和靶向给药等方面的应用研究广泛。与大部分传统的纳米材料相比,DNA四面体可以通过小窝蛋白介导的内吞途径的机制以及微管依赖的途径有序运输到细胞溶酶体内,并且它可以在细胞中保持结构相当长的时间。文献已经报道DNA四面体可以成功的输送免疫刺激剂CpG进入细胞发挥作用,但是同单独的DNA四面体一样,携载的这些药物同样是进入到了细胞的溶酶体中,被溶酶体迅速降解。
AS1411核酸适配体,是可以与核仁素特异结合的DNA单链,核仁素高表达于细胞核上以及肿瘤细胞膜的表面,并且AS1411能经核仁素介导进入细胞核中,同时AS1411可以抑制DNA复制,使细胞停留在S期,从而抑制细胞增殖,同时通过干扰核仁素和bcl-2的结合,从而促进细胞凋亡,因此AS1411在癌症的治疗诊断等方面具有较大的前景。
但将DNA四面体与AS1411以及核酸药物结合起来制备载药系统并未见报道。
发明内容
针对现有技术中的上述不足,本发明提供了一种TDNs-AS1411-核酸药物复合纳米材料载药系统及其制备方法,增加了一种新型的载药系统,同时还有效解决了载药系统所载药物易被溶酶体降解的问题。
为实现上述目的,本发明解决其技术问题所采用的技术方案是:
一种TDNs-AS1411-核酸药物复合纳米材料载药系统的制备方法,包括以下步骤:将AS1411和核酸药物分别与DNA四面体结合,选出分别带有AS1411和核酸药物的四条DNA单链,混合,然后加入TM buffer中,混匀后置于PCR仪内,将温度迅速升到95℃稳定10min,再冷却至4℃稳定20min,得TDNs-AS1411-核酸药物复合纳米材料载药系统。
进一步地,TM buffer为5-10mM Tris-HCl,5-50mM MgCl2,pH8.0。
进一步地,TM buffer为10mM Tris-HCl,50mM MgCl2,pH8.0。
进一步地,分别带有AS1411和核酸药物的四条DNA单链按摩尔比为1:1:1:1混合。
进一步地,分别带有AS1411和核酸药物的四条DNA单链与TM buffer的体积比为1:1:1:1:96。
进一步地,DNA四面体中每条单链浓度为1μM。
进一步地,核酸药物为CpG、反义寡核苷酸、microRNA或siRNA。
CpG为Class-A CpG、Class-B CpG、Class-C CpG或Class-P CpG;更具体地,CpG为Class-A ODN2216、Class-A ODN2336、Class-B ODN2006、Class-C ODN2395或Class-PODN21798。
反义寡核苷酸为ISIS 8005、ISIS 1082、ISIS 2105、ISIS 2302、ISIS 3521、ISIS5132、ISIS 2922、ISIS 1082、ISIS 11061、ISIS 12959或ISIS 481464。
microRNA为miR-34a、miR-1908、miR-302、miR-302d、miR-363、miR-137、miR-210、miR-486-5p、miR-21、miR-196a、miR-140、miR-125a-3p、miR-483-5p、miR-204-5p、miR-540、miR-146b、miR-27、miR-27b、miR-17-5p、miR-106a、miR-22、miR-30c、miR-30、miR-130、miR-138、miR-31、miR-326、miR-135、miR-26a、miR-148b、miR-218、miR-100、miR-196b、miR-92a、miR-193b、miR-194、miR-124、miR-133b或miR-122。
DNA四面体的四条DNA单链序列分别为:
S1:
5’-ATTTATCACCCGCCATAGTAGACGTATCACCAGGCAGTTGAGACGAACATTCCTAAGTCTGAA-3’(SEQ ID NO:1);
S2:
5’-ACATGCGAGGGTCCAATACCGACGATTACAGCTTGCTACACGATTCAGACTTAGGAATGTTCG-3’ (SEQ ID NO:2);
S3:
5’-ACTACTATGGCGGGTGATAAAACGTGTAGCAAGCTGTAATCGACGGGAAGAGCATGCCCATCC-3’ (SEQ ID NO:3);
S4:
5’-ACGGTATTGGACCCTCGCATGACTCAACTGCCTGGTGATACGAGGATGGGCATGCTCTTCCCG-3’ (SEQ ID NO:4)。
由上述方法制备出的TDNs-AS1411-核酸药物复合纳米材料载药系统。
本发明提供的TDNs-AS1411-核酸药物复合纳米材料载药系统及其制备方法,具有以下有益效果:
(1)核酸适体AS1411可以与DNA四面体中的任意一条单链结合,治疗肿瘤疾病的核酸药物也可以与DNA四面体中的任意一条单链结合,当核酸适体AS1411与核酸药物分别挂于DNA四面体中不同的单链时,再与未结合AS1411和核酸药物的DNA单链在特定条件下进行反应,可制备出TDNs-AS1411-核酸药物复合纳米材料载药系统。
(2)TDNs-AS1411-核酸药物复合纳米材料载药系统中TDNs可以在不需要转染剂的情况下进入细胞,并且能将核酸药物携载进入细胞,而AS1411的作用是将其带入细胞核,对肿瘤细胞发挥作用,在细胞中的穿梭过程中,药物不会被溶酶体降解,其靶向性强,同时还不会降低药效。
具体实施方式
实施例1
一种TDNs-AS1411-核酸药物复合纳米材料载药系统的制备方法,包括以下步骤:将AS1411和CpG分别与DNA四面体结合,DNA四面体包括四条DNA单链,DNA单链浓度为1μM,每条链上一个连接位点,一共有四个连接位点, AS1411和CpG均可与DNA四面体中每一条单链(S1、S2 、S3和S4)的5’端结合,其有效结合方式有:①其中一条链与AS1411结合,其余三条链与CpG结合;②其中两条链与AS1411结合,其余两条链与CpG结合;③其中三条链与AS1411结合,其余一条链与CpG结合。
将结合方式①得到的四条单链(摩尔比为1:1:1:1)与TM buffer(10mM Tris-HCl,50mM MgCl2,pH8.0)混合,每条链体积为1μL,TM buffer体积为96μL,总反应体系为100μL,混匀后置于PCR仪内,将温度迅速升到95℃稳定10min,再冷却至4℃稳定20min,得TDNs-AS1411-CpG复合纳米材料载药系统。
可通过6%非变性凝胶电泳(PAGE)、DLS或AFM等方法验证TDNs-AS1411-CpG复合纳米材料载药系统是否制备成功。
4条DNA单链序列分别为:
S1:
5’-ATTTATCACCCGCCATAGTAGACGTATCACCAGGCAGTTGAGACGAACATTCCTAAGTCTGAA-3’ (SEQ ID NO:1);
S2:
5’-ACATGCGAGGGTCCAATACCGACGATTACAGCTTGCTACACGATTCAGACTTAGGAATGTTCG-3’ (SEQ ID NO:2);
S3:
5’-ACTACTATGGCGGGTGATAAAACGTGTAGCAAGCTGTAATCGACGGGAAGAGCATGCCCATCC-3’ (SEQ ID NO:3);
S4:
5’-ACGGTATTGGACCCTCGCATGACTCAACTGCCTGGTGATACGAGGATGGGCATGCTCTTCCCG-3’ (SEQ ID NO:4)。
AS1411可以与DNA四面体中的任意一条单链结合,结合在DNA5’端上,其结合后的序列为:
S1-AS1411:
5’-GGTGGTGGTGGTTGTGGTGGTGGTGGT–ATTTATCACCCGCCATA
GTAGACGTATCACCAGGCAGTTGAGACGAACATTCCTAAGTCTGAA-3’ ( SEQ ID NO:5);
S2-AS1411:
5’-GGTGGTGGTGGTTGTGGTGGTGGTGGT–ACATGCGAGGGTCCAATA
CCGACGATTACAGCTTGCTACACGATTCAGACTTAGGAATGTTCG-3’ ( SEQ ID NO:6);
S3-AS1411:
5’-GGTGGTGGTGGTTGTGGTGGTGGTGGT-ACTACTATGGCGGGTGA
TAAAACGTGTAGCAAGCTGTAATCGACGGGAAGAGCATGCCCATCC-3’ ( SEQ ID NO:7);
S4-AS1411:
5’-GGTGGTGGTGGTTGTGGTGGTGGTGGT-ACGGTATTGGACCCT
CGCATGACTCAACTGCCTGGTGATACGAGGATGGGCATGCTCTTCCCG-3’ ( SEQ ID NO:8);
CpG也可以与DNA四面体中的任意一条单链结合,结合在DNA5’端上,其结合后的序列为:
CpG:
5’-TCCATGACGTTCCTGACG-3’ ( SEQ ID NO:13);
S1-CpG:
5’-TCCATGACGTTCCTGACG-ATTTATCACCCGCCATAGTAGACGTA
TCACCAGGCAGTTGAGACGAACATTCCTAAGTCTGAA-3’( SEQ ID NO:9);
S2-CpG:
5’-TCCATGACGTTCCTGACG-ACATGCGAGGGTCCAATACCGACGATT
ACAGCTTGCTACACGATTCAGACTTAGGAATGTTCG-3’ ( SEQ ID NO:10);
S3-CpG:
5’-TCCATGACGTTCCTGACG-ACTACTATGGCGGGTGATAAAACGT
GTAGCAAGCTGTAATCGACGGGAAGAGCATGCCCATCC-3’(SEQ ID NO:11);
S4-CpG:
5’-TCCATGACGTTCCTGACG-ACGGTATTGGACCCTCGCATGACTCA
ACTGCCTGGTGATACGAGGATGGGCATGCTCTTCCCG-3’ (SEQ ID NO:12)。
实施例2
AS1411、CpG与DNA四面体的结合方式为②,然后与TM buffer混合,其余操作均与实施例1相同。
实施例3
AS1411、CpG与DNA四面体的结合方式为③,然后与TM buffer混合,其余操作均与实施例1相同。
CpG主要是免疫刺激核酸,主要作用是激活细胞的免疫反应从而治疗感染、肿瘤和过敏等疾病;AS1411能够特异性识别癌症细胞膜过表达的核仁素受体,并且通过核仁素的介导作用可在细胞的中穿梭进行细胞核中。DNA四面体上一共有四个连接位点,即可以分别接几个不同的CpG和AS1411:
①当1个连接位点连接CpG,1个位点连接AS1411时,制出的载药系统可以进入细胞核(与DNA四面体单独进入细胞核进行比较),同时具有一定的免疫刺激效应,但是效果相对较弱。
②当1个连接位点连接CpG,2个位点连接AS1411时,制出的载药系统进入细胞核数量增多(与DNA四面体带一个AS1411进入细胞核进行比较),同时具有一定的免疫刺激效应,但是效果还是相对较弱。
③当1个连接位点连接CpG,另外3个位点连接AS1411时,制出的载药系统进入细胞核的数量显著提高(与DNA四面体单独进入细胞核进行比较),但是由于只携载了一个CpG,所以有一定的免疫刺激效应,但是效果不是很强。
④当2个连接位点连接CpG,1个位点连接AS1411时,制出的载药系统可以进入细胞核(与DNA四面体单独进入细胞核进行比较),同时具有一定的免疫刺激效应,效果相对增强。
⑤当2个连接位点连接CpG,另外2个位点连接AS1411时,制出的载药系统进入细胞核的数量提高的更明显(与DNA四面体单独进入细胞核进行比较),进入细胞核的数量也超过了④,同时达到的免疫刺激效也比较强。
⑥当3个连接位点连接CpG,另外1个位点连接AS1411时,制出的载药系统进入细胞核的数量进入细胞核的数量比④和⑤要少,但免疫机制效应却比⑤要强一些。
经综合考虑,选择⑤,其进入细胞核的数量比较多,免疫机制效应也比较强,在细胞核中发挥作用时间比较长。
SEQUENCE LISTING
<110> 四川大学
<120> 一种TDNs-AS1411-核酸药物复合纳米材料载药系统及其制备方法
<130> 2016
<160> 13
<170> PatentIn version 3.3
<210> 1
<211> 63
<212> DNA
<213> S1
<400> 1
atttatcacc cgccatagta gacgtatcac caggcagttg agacgaacat tcctaagtct 60
gaa 63
<210> 2
<211> 63
<212> DNA
<213> S2
<400> 2
acatgcgagg gtccaatacc gacgattaca gcttgctaca cgattcagac ttaggaatgt 60
tcg 63
<210> 3
<211> 63
<212> DNA
<213> S3
<400> 3
actactatgg cgggtgataa aacgtgtagc aagctgtaat cgacgggaag agcatgccca 60
tcc 63
<210> 4
<211> 63
<212> DNA
<213> S4
<400> 4
acggtattgg accctcgcat gactcaactg cctggtgata cgaggatggg catgctcttc 60
ccg 63
<210> 5
<211> 90
<212> DNA
<213> S1-AS1411
<400> 5
ggtggtggtg gttgtggtgg tggtggtatt tatcacccgc catagtagac gtatcaccag 60
gcagttgaga cgaacattcc taagtctgaa 90
<210> 6
<211> 90
<212> DNA
<213> S2-AS1411
<400> 6
ggtggtggtg gttgtggtgg tggtggtaca tgcgagggtc caataccgac gattacagct 60
tgctacacga ttcagactta ggaatgttcg 90
<210> 7
<211> 90
<212> DNA
<213> S3-AS1411
<400> 7
ggtggtggtg gttgtggtgg tggtggtact actatggcgg gtgataaaac gtgtagcaag 60
ctgtaatcga cgggaagagc atgcccatcc 90
<210> 8
<211> 90
<212> DNA
<213> S4-AS1411
<400> 8
ggtggtggtg gttgtggtgg tggtggtacg gtattggacc ctcgcatgac tcaactgcct 60
ggtgatacga ggatgggcat gctcttcccg 90
<210> 9
<211> 81
<212> DNA
<213> S1-CpG
<400> 9
tccatgacgt tcctgacgat ttatcacccg ccatagtaga cgtatcacca ggcagttgag 60
acgaacattc ctaagtctga a 81
<210> 10
<211> 81
<212> DNA
<213> S2-CpG
<400> 10
tccatgacgt tcctgacgac atgcgagggt ccaataccga cgattacagc ttgctacacg 60
attcagactt aggaatgttc g 81
<210> 11
<211> 81
<212> DNA
<213> S3-CpG
<400> 11
tccatgacgt tcctgacgac tactatggcg ggtgataaaa cgtgtagcaa gctgtaatcg 60
acgggaagag catgcccatc c 81
<210> 12
<211> 81
<212> DNA
<213> S4-CpG
<400> 12
tccatgacgt tcctgacgac ggtattggac cctcgcatga ctcaactgcc tggtgatacg 60
aggatgggca tgctcttccc g 81
<210> 13
<211> 18
<212> DNA
<213> CpG
<400> 13
tccatgacgt tcctgacg 18
SEQUENCE LISTING
<110> 四川大学
<120> 一种TDNs-AS1411-核酸药物复合纳米材料载药系统及其制备方法
<130> 2016
<160> 13
<170> PatentIn version 3.3
<210> 1
<211> 63
<212> DNA
<213> S1
<400> 1
atttatcacc cgccatagta gacgtatcac caggcagttg agacgaacat tcctaagtct 60
gaa 63
<210> 2
<211> 63
<212> DNA
<213> S2
<400> 2
acatgcgagg gtccaatacc gacgattaca gcttgctaca cgattcagac ttaggaatgt 60
tcg 63
<210> 3
<211> 63
<212> DNA
<213> S3
<400> 3
actactatgg cgggtgataa aacgtgtagc aagctgtaat cgacgggaag agcatgccca 60
tcc 63
<210> 4
<211> 63
<212> DNA
<213> S4
<400> 4
acggtattgg accctcgcat gactcaactg cctggtgata cgaggatggg catgctcttc 60
ccg 63
<210> 5
<211> 90
<212> DNA
<213> S1-AS1411
<400> 5
ggtggtggtg gttgtggtgg tggtggtatt tatcacccgc catagtagac gtatcaccag 60
gcagttgaga cgaacattcc taagtctgaa 90
<210> 6
<211> 90
<212> DNA
<213> S2-AS1411
<400> 6
ggtggtggtg gttgtggtgg tggtggtaca tgcgagggtc caataccgac gattacagct 60
tgctacacga ttcagactta ggaatgttcg 90
<210> 7
<211> 90
<212> DNA
<213> S3-AS1411
<400> 7
ggtggtggtg gttgtggtgg tggtggtact actatggcgg gtgataaaac gtgtagcaag 60
ctgtaatcga cgggaagagc atgcccatcc 90
<210> 8
<211> 90
<212> DNA
<213> S4-AS1411
<400> 8
ggtggtggtg gttgtggtgg tggtggtacg gtattggacc ctcgcatgac tcaactgcct 60
ggtgatacga ggatgggcat gctcttcccg 90
<210> 9
<211> 81
<212> DNA
<213> S1-CpG
<400> 9
tccatgacgt tcctgacgat ttatcacccg ccatagtaga cgtatcacca ggcagttgag 60
acgaacattc ctaagtctga a 81
<210> 10
<211> 81
<212> DNA
<213> S2-CpG
<400> 10
tccatgacgt tcctgacgac atgcgagggt ccaataccga cgattacagc ttgctacacg 60
attcagactt aggaatgttc g 81
<210> 11
<211> 81
<212> DNA
<213> S3-CpG
<400> 11
tccatgacgt tcctgacgac tactatggcg ggtgataaaa cgtgtagcaa gctgtaatcg 60
acgggaagag catgcccatc c 81
<210> 12
<211> 81
<212> DNA
<213> S4-CpG
<400> 12
tccatgacgt tcctgacgac ggtattggac cctcgcatga ctcaactgcc tggtgatacg 60
aggatgggca tgctcttccc g 81
<210> 13
<211> 18
<212> DNA
<213> CpG
<400> 13
tccatgacgt tcctgacg 18
Claims (10)
1.一种TDNs-AS1411-核酸药物复合纳米材料载药系统的制备方法,其特征在于,包括以下步骤:将AS1411和核酸药物分别与DNA四面体结合,选出分别带有AS1411和核酸药物的四条DNA单链,混合,然后加入TM buffer中,混匀后置于PCR仪内,将温度迅速升到95℃稳定10min,再冷却至4℃稳定20min,得TDNs-AS1411-核酸药物复合纳米材料载药系统。
2.根据权利要求1所述的TDNs-AS1411-核酸药物复合纳米材料载药系统的制备方法,其特征在于,TM buffer为5-10mM Tris-HCl,5-50mM MgCl2,pH8.0。
3.根据权利要求2所述的TDNs-AS1411-核酸药物复合纳米材料载药系统的制备方法,其特征在于,TM buffer为10mM Tris-HCl,50mM MgCl2,pH8.0。
4.根据权利要求1所述的TDNs-AS1411-核酸药物复合纳米材料载药系统的制备方法,其特征在于,分别带有AS1411和核酸药物的四条DNA单链按摩尔比为1:1:1:1混合。
5.根据权利要求1所述的TDNs-AS1411-核酸药物复合纳米材料载药系统的制备方法,其特征在于,分别带有AS1411和核酸药物的四条DNA单链与TM buffer的体积比为1:1:1:1:96。
6.根据权利要求1所述的TDNs-AS1411-核酸药物复合纳米材料载药系统的制备方法,其特征在于,DNA四面体中每条单链浓度为1μM。
7.根据权利要求1所述的TDNs-AS1411-核酸药物复合纳米材料载药系统的制备方法,其特征在于,核酸药物为CpG、反义寡核苷酸、microRNA或siRNA。
8.根据权利要求1所述的TDNs-AS1411-核酸药物复合纳米材料载药系统的制备方法,其特征在于,CpG为Class-A CpG、Class-B CpG、Class-C CpG或Class-P CpG。
9.根据权利要求1所述的TDNs-AS1411-核酸药物复合纳米材料载药系统的制备方法,其特征在于,反义寡核苷酸为ISIS 8005、ISIS 1082、ISIS 2105、ISIS 2302、ISIS 3521、ISIS 5132、ISIS 2922、ISIS 1082、ISIS 11061、ISIS 12959或ISIS 481464。
10.权利要求1-9任一项所述方法制备的TDNs-AS1411-核酸药物复合纳米材料载药系统。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610940890.3A CN106540268B (zh) | 2016-11-02 | 2016-11-02 | 一种TDNs-AS1411-核酸药物复合纳米材料载药系统及其制备方法 |
US15/555,380 US10507246B2 (en) | 2016-11-02 | 2016-11-21 | TDNs-AS1411-nucleic acid drug nanocomposite based drug delivery system and preparation method thereof |
PCT/CN2016/106627 WO2018082126A1 (zh) | 2016-11-02 | 2016-11-21 | 一种TDNs-AS1411-核酸药物复合纳米材料载药系统及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610940890.3A CN106540268B (zh) | 2016-11-02 | 2016-11-02 | 一种TDNs-AS1411-核酸药物复合纳米材料载药系统及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106540268A true CN106540268A (zh) | 2017-03-29 |
CN106540268B CN106540268B (zh) | 2021-01-26 |
Family
ID=58393387
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610940890.3A Active CN106540268B (zh) | 2016-11-02 | 2016-11-02 | 一种TDNs-AS1411-核酸药物复合纳米材料载药系统及其制备方法 |
Country Status (3)
Country | Link |
---|---|
US (1) | US10507246B2 (zh) |
CN (1) | CN106540268B (zh) |
WO (1) | WO2018082126A1 (zh) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107669697A (zh) * | 2017-11-22 | 2018-02-09 | 四川大学 | Dna四面体在抑制阿尔兹海默细胞凋亡中的应用 |
CN107805643A (zh) * | 2017-09-15 | 2018-03-16 | 四川大学 | 靶向抑制沙门氏菌耐药外排泵基因acrA的siRNA‑DNA纳米系统及其制备方法 |
CN107881149A (zh) * | 2017-11-22 | 2018-04-06 | 四川大学 | Dna四面体在促进神经干细胞增殖分化过程中的应用 |
CN109364261A (zh) * | 2018-11-05 | 2019-02-22 | 中国科学院上海应用物理研究所 | 一种基于框架核酸的可控经皮给药制剂及其制备方法 |
CN109364255A (zh) * | 2017-09-12 | 2019-02-22 | 四川大学 | 一种阳离子聚合物/TDNs载药复合物及其制备方法和用途 |
CN109663134A (zh) * | 2019-01-30 | 2019-04-23 | 四川大学 | 5-氟尿嘧啶和as1411修饰的dna四面体 |
WO2019101116A1 (zh) * | 2017-11-22 | 2019-05-31 | 四川大学 | Dna四面体在促神经修复药物制备中的用途 |
CN109985057A (zh) * | 2019-04-15 | 2019-07-09 | 四川大学 | 四面体骨架核酸在制备皮肤修复的药物中的用途 |
CN110404081A (zh) * | 2019-08-26 | 2019-11-05 | 四川大学 | 一种DNA四面体和microRNA的纳米复合物 |
CN110917121A (zh) * | 2019-12-11 | 2020-03-27 | 四川大学 | 一种apd杂化纳米系统及其构建方法和应用 |
CN111729088A (zh) * | 2020-08-21 | 2020-10-02 | 江苏申基生物科技有限公司 | 一种微小核糖核酸miR-34a偶联探针及其制备方法 |
CN112587652A (zh) * | 2020-06-18 | 2021-04-02 | 四川大学 | 一种抑制真菌生长的药物 |
CN113134093A (zh) * | 2021-04-14 | 2021-07-20 | 华中科技大学 | 一种dna四面体纳米结构作为治疗内耳疾病药物的载体的应用 |
CN113521295A (zh) * | 2020-04-21 | 2021-10-22 | 湖南大学 | 一种负载核酸适体药物偶联物的dna八面体结构 |
CN113750259A (zh) * | 2021-08-05 | 2021-12-07 | 中南大学 | 一种具有靶向激活能力的dna纳米系统及其构建方法和应用 |
CN114377122A (zh) * | 2022-01-18 | 2022-04-22 | 四川大学 | 一种基于四面体框架核酸的复合佐剂、mRNA疫苗及其制备方法和用途 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109679961A (zh) * | 2018-11-13 | 2019-04-26 | 南方医科大学南方医院 | 一种自组装树状纳米复合物及其应用 |
US20210123057A1 (en) * | 2019-10-29 | 2021-04-29 | Northwestern University | Sequence Multiplicity Within Spherical Nucleic Acids |
CN115121803B (zh) * | 2021-03-11 | 2024-04-30 | 上海交通大学医学院附属仁济医院 | 一种基于dna框架结构的多聚纳米团簇的合成方法 |
CN113769107A (zh) * | 2021-09-16 | 2021-12-10 | 泉州师范学院 | 一种双靶向dna纳米载药复合体的制备方法及其用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104651491A (zh) * | 2014-12-23 | 2015-05-27 | 中国科学院上海高等研究院 | 一种dna四面体纳米结构信号探针及其应用 |
CN104774857A (zh) * | 2015-04-21 | 2015-07-15 | 中国科学院上海高等研究院 | 一种dna三维纳米结构人工酶前体及其制备与应用 |
CN105366730A (zh) * | 2015-11-26 | 2016-03-02 | 福州大学 | 一种使用dna纳米结构对疏水性纳米粒子相转换的方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104645338B (zh) | 2015-01-26 | 2018-05-04 | 上海交通大学 | 一种针对脑肿瘤的dna靶向纳米载药分子的制备方法 |
CN104784703A (zh) * | 2015-04-20 | 2015-07-22 | 北京工业大学 | 一种基于适配体靶向递送microRNA的纳米载体及其制备方法与应用 |
CN105296491B (zh) * | 2015-11-27 | 2018-06-15 | 北京大学 | 一种经化学修饰后的核酸适配体as1411及其用途 |
-
2016
- 2016-11-02 CN CN201610940890.3A patent/CN106540268B/zh active Active
- 2016-11-21 US US15/555,380 patent/US10507246B2/en active Active
- 2016-11-21 WO PCT/CN2016/106627 patent/WO2018082126A1/zh active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104651491A (zh) * | 2014-12-23 | 2015-05-27 | 中国科学院上海高等研究院 | 一种dna四面体纳米结构信号探针及其应用 |
CN104774857A (zh) * | 2015-04-21 | 2015-07-15 | 中国科学院上海高等研究院 | 一种dna三维纳米结构人工酶前体及其制备与应用 |
CN105366730A (zh) * | 2015-11-26 | 2016-03-02 | 福州大学 | 一种使用dna纳米结构对疏水性纳米粒子相转换的方法 |
Non-Patent Citations (2)
Title |
---|
JIANG LI,ET AL.: "Self-assembled multivalent DNA nanostructures for noninvasive intracellular delivery of immunostimulatory CpG oligonucleotides", 《ACSNANO》 * |
XIAOBO XU,ET AL.: "G4-tetra DNA duplex induce lung cancer cell apoptosis in A549 cells", 《NANOSCALE RESEARCH LETTERS》 * |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109364255A (zh) * | 2017-09-12 | 2019-02-22 | 四川大学 | 一种阳离子聚合物/TDNs载药复合物及其制备方法和用途 |
CN107805643B (zh) * | 2017-09-15 | 2020-12-08 | 四川大学 | 靶向抑制沙门氏菌耐药外排泵基因acrA的siRNA-DNA纳米系统及其制备方法 |
CN107805643A (zh) * | 2017-09-15 | 2018-03-16 | 四川大学 | 靶向抑制沙门氏菌耐药外排泵基因acrA的siRNA‑DNA纳米系统及其制备方法 |
CN107881149A (zh) * | 2017-11-22 | 2018-04-06 | 四川大学 | Dna四面体在促进神经干细胞增殖分化过程中的应用 |
WO2019100727A1 (zh) * | 2017-11-22 | 2019-05-31 | 四川大学 | Dna四面体在抑制阿尔兹海默细胞凋亡中的应用 |
WO2019100726A1 (zh) * | 2017-11-22 | 2019-05-31 | 四川大学 | Dna四面体在促进神经干细胞增殖分化过程中的应用 |
WO2019101116A1 (zh) * | 2017-11-22 | 2019-05-31 | 四川大学 | Dna四面体在促神经修复药物制备中的用途 |
CN107669697A (zh) * | 2017-11-22 | 2018-02-09 | 四川大学 | Dna四面体在抑制阿尔兹海默细胞凋亡中的应用 |
CN109364261A (zh) * | 2018-11-05 | 2019-02-22 | 中国科学院上海应用物理研究所 | 一种基于框架核酸的可控经皮给药制剂及其制备方法 |
CN109364261B (zh) * | 2018-11-05 | 2021-12-03 | 中国科学院上海应用物理研究所 | 一种基于框架核酸的可控经皮给药制剂及其制备方法 |
CN109663134B (zh) * | 2019-01-30 | 2021-09-17 | 四川大学 | 5-氟尿嘧啶和as1411修饰的dna四面体 |
CN109663134A (zh) * | 2019-01-30 | 2019-04-23 | 四川大学 | 5-氟尿嘧啶和as1411修饰的dna四面体 |
CN109985057A (zh) * | 2019-04-15 | 2019-07-09 | 四川大学 | 四面体骨架核酸在制备皮肤修复的药物中的用途 |
CN109985057B (zh) * | 2019-04-15 | 2021-03-12 | 成都腾达树纳米生物科技有限公司 | 四面体骨架核酸在制备皮肤修复的药物中的用途 |
CN110404081A (zh) * | 2019-08-26 | 2019-11-05 | 四川大学 | 一种DNA四面体和microRNA的纳米复合物 |
CN110917121B (zh) * | 2019-12-11 | 2021-01-05 | 四川大学 | 一种apd杂化纳米系统及其构建方法和应用 |
CN110917121A (zh) * | 2019-12-11 | 2020-03-27 | 四川大学 | 一种apd杂化纳米系统及其构建方法和应用 |
CN113521295A (zh) * | 2020-04-21 | 2021-10-22 | 湖南大学 | 一种负载核酸适体药物偶联物的dna八面体结构 |
CN113521295B (zh) * | 2020-04-21 | 2022-07-01 | 湖南大学 | 一种负载核酸适体药物偶联物的dna八面体结构 |
CN112587652A (zh) * | 2020-06-18 | 2021-04-02 | 四川大学 | 一种抑制真菌生长的药物 |
CN112587652B (zh) * | 2020-06-18 | 2022-09-16 | 四川大学 | 一种抑制真菌生长的药物 |
CN111729088A (zh) * | 2020-08-21 | 2020-10-02 | 江苏申基生物科技有限公司 | 一种微小核糖核酸miR-34a偶联探针及其制备方法 |
CN113134093A (zh) * | 2021-04-14 | 2021-07-20 | 华中科技大学 | 一种dna四面体纳米结构作为治疗内耳疾病药物的载体的应用 |
CN113134093B (zh) * | 2021-04-14 | 2022-05-13 | 华中科技大学 | 一种dna四面体纳米结构作为内耳疾病药物的载体的应用 |
CN113750259A (zh) * | 2021-08-05 | 2021-12-07 | 中南大学 | 一种具有靶向激活能力的dna纳米系统及其构建方法和应用 |
CN114377122A (zh) * | 2022-01-18 | 2022-04-22 | 四川大学 | 一种基于四面体框架核酸的复合佐剂、mRNA疫苗及其制备方法和用途 |
CN114377122B (zh) * | 2022-01-18 | 2023-04-07 | 四川大学 | 一种基于四面体框架核酸的复合佐剂、mRNA疫苗及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN106540268B (zh) | 2021-01-26 |
US10507246B2 (en) | 2019-12-17 |
US20180344863A1 (en) | 2018-12-06 |
WO2018082126A1 (zh) | 2018-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106540268A (zh) | 一种TDNs‑AS1411‑核酸药物复合纳米材料载药系统及其制备方法 | |
US9416369B2 (en) | Methods and compositions to modulate RNA processing | |
McDermott et al. | The therapeutic potential of microRNAs: disease modulators and drug targets | |
Simonson et al. | MicroRNA therapeutics: the next magic bullet? | |
US10745440B2 (en) | Peptides and nanoparticles for intracellular delivery of molecules | |
KR101328568B1 (ko) | Rna 간섭을 유도하는 핵산 분자 및 그 용도 | |
Li et al. | MicroRNAs dysregulation in epilepsy | |
JP2017524341A (ja) | ハイブリッドtRNA/プレmiRNA分子および使用方法 | |
EP3018208B1 (en) | Improved nanoparticle type oligonucleotide structure having high efficiency and method for preparing same | |
JP2014506789A (ja) | miR−124の合成模倣体 | |
Wu et al. | MiRNAs in human cancers: the diagnostic and therapeutic implications | |
Luo et al. | microRNA133a targets Foxl2 and promotes differentiation of C2C12 into myogenic progenitor cells | |
Cha et al. | MicroRNAs as novel endogenous targets for regulation and therapeutic treatments | |
de Franciscis | Challenging cancer targets for aptamer delivery | |
CN102191246B (zh) | 多靶标干扰核酸分子及其应用 | |
Asakiya et al. | Current progress of miRNA-derivative nucleotide drugs: modifications, delivery systems, applications | |
US20230129651A1 (en) | Hairpin structure nucleic acid molecules capable of modulating target gene expression and uses thereof | |
US20230304006A1 (en) | Anti-seed pnas and microrna inhibition | |
KR102267479B1 (ko) | miRNA 억제제-알부민의 복합체를 유효성분으로 포함하는 암 치료제 | |
Al Hasan et al. | Small RNA-mediated prevention, diagnosis and therapies of cancer | |
WO2020033938A1 (en) | Programmable conditional sirnas and uses thereof | |
CN102199603B (zh) | 多靶位干扰rna分子及其应用 | |
US20230193262A1 (en) | Nucleic acid molecules capable of modulating target gene expression and uses thereof | |
Paul et al. | Extracellular Vesicles: Applications and Therapeutic Potential | |
Menjivar et al. | MicroRNA Nano-Shuttles: Engineering Extracellular Vesicles as a Cutting-Edge Biotechnology Platform for Clinical Use in Therapeutics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240621 Address after: Room 1-17, 15th Floor, Building 2, No. 89, North Section 4, Second Ring Road, Jinniu District, Chengdu City, Sichuan Province, 610000 Patentee after: Chengdu Yunhai Tetrahedral Biotechnology Co.,Ltd. Country or region after: China Address before: 610064, No. 24, south section of first ring road, Chengdu, Sichuan, Wuhou District Patentee before: SICHUAN University Country or region before: China |